Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP Sells $1,008,000.00 in Stock

Bio-Rad Laboratories, Inc. (NYSE:BIOGet Free Report) EVP Michael Crowley sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the transaction, the executive vice president now directly owns 6,942 shares in the company, valued at $2,332,512. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Bio-Rad Laboratories Stock Performance

Shares of NYSE BIO traded up $0.61 during midday trading on Wednesday, hitting $330.35. The company’s stock had a trading volume of 219,587 shares, compared to its average volume of 215,552. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.34 and a current ratio of 5.83. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $509.62. The firm’s fifty day moving average price is $323.71 and its 200-day moving average price is $331.64. The firm has a market cap of $9.42 billion, a P/E ratio of -15.37 and a beta of 0.89.

Bio-Rad Laboratories (NYSE:BIOGet Free Report) last issued its earnings results on Thursday, February 15th. The medical research company reported $3.10 EPS for the quarter, beating analysts’ consensus estimates of $2.93 by $0.17. The company had revenue of $681.18 million during the quarter, compared to the consensus estimate of $685.00 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. Bio-Rad Laboratories’s quarterly revenue was down 6.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.31 earnings per share. On average, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 11.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Bio-Rad Laboratories

Institutional investors have recently modified their holdings of the company. Quarry LP acquired a new stake in Bio-Rad Laboratories in the 4th quarter valued at approximately $27,000. Farther Finance Advisors LLC raised its stake in shares of Bio-Rad Laboratories by 42.3% during the second quarter. Farther Finance Advisors LLC now owns 101 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 30 shares in the last quarter. Gladius Capital Management LP lifted its holdings in Bio-Rad Laboratories by 65.8% in the fourth quarter. Gladius Capital Management LP now owns 121 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares during the period. Principal Securities Inc. acquired a new stake in Bio-Rad Laboratories in the fourth quarter worth about $41,000. Finally, GAMMA Investing LLC bought a new position in Bio-Rad Laboratories in the 4th quarter valued at about $42,000. Institutional investors own 63.98% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on BIO shares. Royal Bank of Canada cut their price target on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. UBS Group boosted their price objective on Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday. Five analysts have rated the stock with a buy rating, According to, the stock currently has a consensus rating of “Buy” and a consensus target price of $493.75.

Get Our Latest Research Report on BIO

Bio-Rad Laboratories Company Profile

(Get Free Report)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Featured Articles

Insider Buying and Selling by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with's FREE daily email newsletter.